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Background-—Smoker’s paradox has been observed with several vascular disorders, yet there are limited data in patients with
acute heart failure (HF). We examined the effects of smoking in patients with acute HF using data from a large multicenter registry.
The objective was to determine if the design and analytic approach could explain the smoker’s paradox in acute HF mortality.
Methods and Results-—The data were sourced from the acute HF registry (Gulf CARE [Gulf Acute Heart Failure Registry]), a
multicenter registry that recruited patients over 10 months admitted with a diagnosis of acute HF from 47 hospitals in 7 Middle
Eastern countries. The association between smoking and mortality (in hospital) was examined using covariate adjustment, making
use of mortality risk factors. A parallel analysis was performed using covariate balancing through propensity scores. Of 5005
patients hospitalized with acute HF, 1103 (22%) were current smokers. The in-hospital mortality rates were significantly lower in
current smoker’s before (odds ratio, 0.71; 95% CI, 0.52–0.96) and more so after (odds ratio, 0.47; 95% CI, 0.31–0.70) covariate
adjustment. With the propensity score–derived covariate balance, the smoking effect became much less certain (odds ratio, 0.63;
95% CI, 0.36–1.11).
Conclusions-—The current study illustrates the fact that the smoker’s paradox is likely to be a result of residual confounding as
covariate adjustment may not resolve this if there are many competing prognostic confounders. In this situation, propensity score
methods for covariate balancing seem preferable.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01467973. ( J Am Heart Assoc. 2019;8:
e013056. DOI: 10.1161/JAHA.119.013056.)
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S moking is a strong risk factor for premature atheroscle-rosis, myocardial infarction (MI), heart failure (HF), and
sudden cardiac death. It is estimated that smokers lose at
least one decade of life expectancy, compared with those who
have never smoked.1 Yet, despite the well-established and
modifiable risk associated with smoking, several studies have
demonstrated that the short-term mortality after acute
coronary syndromes (ACSs) or associated HF2 is lower in
current smokers (CSs) compared with current nonsmokers
(CNs), the so-called smoker’s paradox.3 This apparent
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paradox, whereby CS subjects appear to have more favorable
outcomes compared with CN subjects, has also been reported
in other disease states, including stroke,4 trauma,5 cardiac
arrest,6 and preeclampsia.7
Smoking perhaps is not the variable that improves the
outcome; it is more likely confounded by the different baseline
variables that worsen outcome and are likely to induce smoking
cessation, most important factors related to severity of illness.8
The conventional approach used in research has been to adjust
for such baseline characteristics when looking for a causal
association from observational data.9 In the latter, an attempt is
then made to incorporate key important covariates into a
regression model examining the relationship between the
exposure and the outcome. Studies using this approach seem
to confirm the presence of such a smoking paradox, the paradox
being thatCSseems tobea “cause”of the improved prognosis.10
Unfortunately, such regression models may be overfitted
when the numbers with the outcome are small compared with
the number of participants and confounders. In addition, the
adequacy of model specification needs to be checked and the
relationship between the third variables and the outcome needs
to meet model specifications (eg, linear within a linear model).
All these are potential problems; and despite the fact that
standard guidelines suggest having no less than 10 events for
each covariate incorporated into the model,11 it may not be
possible to adhere to this when important confounders are
many, as is the case in observational research in ACS andHF. An
alternative strategy that has emerged is the propensity score
(PS), which is progressively being used in observational studies
of cardiovascular interventions.12–14 A PS is characterized as
the likelihood of a patient being allocated to an intervention,
given a set of exposures.15 As the PS reduces many patient
covariates into a single covariate, it decreases the probability of
overfitting.16 The goal of the PS technique is to attain covariate
balance, as is the case with randomized comparisons.
In this study, we decided to compare the covariate adjust-
ment and PS approach to examine, in detail, the effect of
smoking status on the in-hospital mortality of patients hospi-
talizedwith acute HF using data from amulticentermultinational
HF registry: the Gulf CARE (Gulf Acute Heart Failure Registry).
Methods
Data will be available from the corresponding author on
reasonable request.
Registry Design
Details of the Gulf CARE design were previously pub-
lished.17,18 In summary, Gulf CARE was a multicenter,
multinational, prospective, observational study that recruited
patients who were admitted with the final diagnosis of acute
HF from 47 hospitals in 7 Middle Eastern countries in the
Arabian Gulf (Oman, Saudi Arabia, United Arab Emirates,
Qatar, Bahrain, Yemen, and Kuwait) during February 2012 to
November 2012.17 Data were collected on episodes of
hospitalization, as per a standardized case report form
beginning with point of initial care, and including patient’s
discharge, transfer out of hospital, or in-hospital death, and
for those discharged alive at 3 and at 12 months of follow-up.
Study ethical approval was obtained from all concerned
authorities in the recruiting centers. Informed consent was
obtained from all patients. Each patient was given a unique
identification number to prevent double counting.
Study included patients with acute HF from both sexes who
were ≥18 years of age and admitted to the participating
hospitals. Acute HF was defined on the basis of the European
Society of Cardiology definition.19 Acute HF was further
classified as either acute decompensated chronic HF or new-
onset acute HF (de novo) based on European Society of
Cardiology guidelines.19 Acute decompensated chronic HF was
defined as worsening of HF in patients with a previous diagnosis
or hospitalization for HF. New-onset acute HF (de novo) was
defined as acute HF in patients with no history of HF.
Patients were excluded from the study if the following
occurred: (1) they were discharged from the emergency
department without admission, (2) they were transferred from
a nonregistry hospital, (3) they could not provide informed
Clinical Perspective
What Is New?
• This study examined the smoking paradox in relation to
confounding by severity of illness related variables in a
Middle Eastern population admitted for heart failure.
• The relationship between smoking behavior at admission
and mortality is reexamined from a methodological per-
spective comparing traditional covariate adjustment with
covariate balancing via propensity score–based weights.
What Are the Clinical Implications?
• The smoking paradox is probably not a causal effect but
rather a bias that has been incompletely addressed
analytically.
• There are many confounding variables related to severity of
illness in registry-based observational cardiovascular stud-
ies, making residual confounding a serious problem when
assessing causal effects, on outcome, of specific factors
(such as smoking).
• The results in this article suggest that covariate balancing
using propensity score–based weights can help avoid such
paradoxical results when compared with traditional covari-
ate adjustment in the assessment of causal effects.
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consent, and (4) their final diagnosis was not HF.
Registry organization and data collection and validation have
already been outlined in a prior published article of Gulf
CARE.17,18
Definitions of variables in the case report form were based
on the European Society of Cardiology guidelines 2008 and
the American College of Cardiology clinical data standards
2005.19,20 Diabetes mellitus (DM) was defined as having a
history of DM diagnosed and treated with medication and/or
insulin or fasting blood glucose of 7.0 mmol/L (126 mg/dL)
or glycated hemoglobin ≥6.5%. Hypertension was defined as
having a history of hypertension diagnosed and treated with
medication, blood pressure >140 mm Hg systolic or
>90 mm Hg diastolic on at least 2 occasions, or blood
pressure >130 mm Hg systolic or >80 mm Hg diastolic on at
least 2 occasions, for patients with DM or chronic kidney
disease (CKD). Hyperlipidemia was defined as history of
dyslipidemia diagnosed and/or treated by a physician or total
cholesterol >5.18 mmol/L (200 mg/dL), low-density lipopro-
tein cholesterol ≥3.37 mmol/L (130 mg/dL), or high-density
lipoprotein cholesterol <1.04 mmol/L (40 mg/dL). CS was
defined as smoking cigarettes, water pipe, cigar, or chewing
tobacco within 1 month of index admission. CKD was defined
as glomerular filtration rate <60 mL/min per 1.73 m2 for
≥3 months, with or without kidney damage or on dialysis. If
no glomerular filtration rate was available, serum creatinine
>177 mmol/L or 2 mg/dL was marked as CKD. Obesity was
defined as body mass index >25 kg/m2. Cardiomyopathy was
defined as a myocardial disorder in which the heart muscle is
structurally and functionally abnormal (in the absence of
coronary artery disease [CAD], hypertension, valvular disease,
or congenital heart disease), sufficient to cause the observed
myocardial abnormality. Infection definition in the registry was
any systemic infection needing antibiotics. The presence of
CAD was defined as history of CAD, MI, or coronary
revascularization procedure, including percutaneous coronary
intervention and coronary artery bypass grafting surgery.
Statistical Analysis
Baseline and outcome data were presented as frequency and
percentages for categorical variables; and for interval vari-
ables, they were presented as means and SDs (and median
and interquartile range for nonnormally distributed variables),
as appropriate. v2 Tests (or Fisher exact tests for cells <5)
were applied to see if there were associations between CSs
and CNs for categorical variables, whereas Student t tests
were used for normally distributed interval variables and
Wilcoxon rank sum tests were used for nonnormally dis-
tributed interval variables. The association between smoking
and mortality (in hospital) was examined using multivariable
logistic regression, adjusting for risk factors potentially
related to mortality. These included 3 from demographics:
age, sex, and country of origin in the Gulf Cooperation Council
countries; 9 from previous history: prior DM, prior CKD/
dialysis, prior hyperlipidemia, prior CAD, prior asthma/chronic
obstructive pulmonary disease, prior ACS, prior admission for
HF, prior syncope in past 1 year, and prior use of aspirin; 3
from admission status: body mass index on admission, New
York Heart Association class at admission, and admitted to
intensive care unit; and, finally, 2 from course in hospital:
intubation/ventilation and atrial fibrillation requiring therapy.
Adjusted odds ratios (ORs) and 95% CIs were used to quantify
the association between baseline variables and mortality.
In the second analysis, the PS for an individual was defined
as the probability of being in the exposure group given all
relevant covariates. The PS was estimated using a logistic
regression model that incorporated all variables listed above
used for the covariate adjustment model. After the PS was
calculated, weights were applied to the regression model
corresponding to 1/PS for patients in the CS cohort and [1/
(1PS)] for those in the CN cohort. No trimming was
performed of these weights in the main analysis, but a
sensitivity analysis restricting data to a subsample with PS
between 0.01 and 0.99 as well as between 0.1 and 0.9 was
performed as a sensitivity analysis. The weighted data were
checked for covariate balance using standardized differences
between CS and CN subjects before and after weighting. On
the graph of standardized differences, horizontal lines denot-
ing standardized differences of 0.1 are indicated as it has
been suggested that standardized differences that exceed
these thresholds may be indicative of meaningful imbal-
ance.21 For comparison, we provide the crude effect estimate,
the covariate-adjusted effect estimate, and the PS model
weighted estimate. P<0.05 (2 tailed) was considered statis-
tically significant. Stata, version 15 (StataCorp, College
Station, TX), was used for the analysis.
Results
Baseline Characteristics
The study included 5005 patients hospitalized with acute HF,
of whom 1103 (22%) were CSs. CS subjects were 6 years
younger and more likely to present with acute decompen-
sated chronic HF. Compared with nonsmokers, smokers were
less likely to present with a history of CAD, left ventricular
dysfunction, valvular heart disease, stroke/transient ischemic
attacks, DM, hypertension, hyperlipidemia, CKD, asthma/
chronic obstructive pulmonary disease, and thyroid disease,
whereas CN subjects were more likely to have family history
of cardiomyopathy/HF. CS subjects were less likely to be
taking aspirin, digoxin, oral nitrates, and other evidence-based
medications before admission (Table 1).
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Table 1. Baseline Characteristics of Subjects in the Registry
Characteristics
Smokers
(n=1103; 22%)
Nonsmokers
(n=3902; 78%) P Value
HF type
Acute new-onset HF 428 (39) 2289 (59) 0.001
Acute decompensated chronic HF 675 (61) 1613 (41)
Age, meanSD, y 5512 6115 0.001
Women 83 (7.5) 1791 (46) 0.001
Ethnicity/race
Arab 945 (85.7) 3571 (91.5)
Asian 154 (14) 319 (8.2)
Other 4 (0.4) 12 (0.3)
Previous cardiovascular history
Known systolic LV dysfunction 351 (32) 1930 (50) 0.001
Known CAD 432 (39) 1905 (49) 0.001
Valvular heart disease 63 (6) 612 (16) 0.001
Congenital heart disease 7 (0.6) 34 (0.9) 0.44
PVD 46 (4) 177 (4.5) 0.60
Stroke/TIA 65 (6) 339 (8.7) 0.003
Family history of
cardiomyopathy/heart failure
96 (8.7) 163 (4) 0.001
Other comorbidities
Diabetes mellitus 439 (40) 2053 (53) 0.001
Hypertension 540 (49) 2519 (65) 0.001
Hyperlipidemia 345 (31) 1454 (37) 0.001
CKD/dialysis 69 (6) 675 (17) 0.001
Sleep apnea requiring therapy 11 (1) 88 (2.3) 0.008
Asthma/COPD 88 (8) 413 (10.6) 0.01
Thyroid disease 8 (0.7) 173 (4.4) 0.001
Clinical and biochemical parameters
HR, meanSD, bpm 10020 9623 0.001
Systolic blood pressure, meanSD, mm Hg 13733 13734 0.95
Diastolic blood pressure, meanSD, mm Hg 8519 8020 0.001
RR, median (IQR), /min 25 (22–29) 24 (20–28) 0.001
BMI, meanSD, kg/m2 275 286.6 0.001
Pulse oximetry saturation, meanSD, % 926 937 0.88
NT-proBNP, median (IQR), pg/mL 3324 (1445–6246) 3190 (1313–7428) 0.06
Elevated troponin 458 (42) 1444 (37) 0.006
HbA1c, meanSD, % 7.02.4 7.32.0 0.07
Total cholesterol, meanSD, mmol/L 5.52.7 4.62.1 0.001
Creatinine, meanSD, lmol/L 123112 132117 0.03
ECG rhythm AF/flutter 79 (7) 600 (15) 0.001
LVEF, meanSD, % 3512.5 3714 0.001
Continued
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Precipitating Factors for HF Hospitalization
ACS was significantly more common in CSs, whereas
noncompliance with diet, uncontrolled arrhythmias, and
systemic infections were more common in CNs as possible
precipitating factors for hospitalization. (Table 1)
Clinical and Biochemical Parameters
On presentation, CSs had significantly lower rates of atrial
arrhythmia and a lower mean ejection fraction. CSs had
higher rates of serum troponin and a lower creatinine
compared with CNs (Table 1).
In-Hospital Course
CSs were more likely to be treated with inotropes, whereas
the rates of noninvasive ventilations and acute dialysis or
blood transfusion for major bleeding were more commonly
used in CNs. Also, CNs were more likely to have systemic
infections requiring antibiotics. The rates of invasive ventila-
tion, intra-aortic balloon pump insertion, and the risk of
development of stroke were comparable between the 2
groups. At discharge, CSs were more likely to be prescribed
digoxin, aspirin, clopidogrel, b blockers, angiotensin-convert-
ing enzyme inhibitors, and aldosterone antagonists, whereas
CNs were more likely to be discharged on hydralazine and oral
anticoagulants. Cardiac procedures, including interventions
and device therapy, were low in the 2 groups, with percuta-
neous coronary interventions performed more often in CSs.
The CS subjects had higher rates of ventricular tachycardia/
fibrillation requiring therapy, whereas CNs had higher rates of
atrial fibrillation requiring therapy. The crude in-hospital
mortality rate was lower in CSs than CNs (4.8% versus
6.7%; P=0.02) (Table 2).
Regression Models
The crude OR for in-hospital mortality, according to smoking
status (CS versus CN) at admission, was 0.71 (95% CI, 0.52–
0.96; P=0.025). Multivariable logistic regression using covari-
ate adjustment to determine the possibility of a causal effect
of smoking on in-hospital mortality revealed an even stronger
protective effect for CS, with 50% reduction in odds of in-
hospital mortality (OR, 0.47; 95% CI, 0.31–0.70; P<0.001),
Using untrimmed PS values, the inverse probability of
exposure-weighted logistic regression with robust error
variances resulted in a mortality OR of 0.63 (95% CI, 0.36–
1.11; P=0.11). The trimmed data sets revealed a similar result
after exclusion of 285 subjects (retained if PS values were
between 0.01 and 0.99); the in-hospital mortality OR for CS
was 0.71 (95% CI, 0.41–1.24; P=0.233). After exclusion of
2057 subjects (retained if PS values were between 0.1 and
0.9), the in-hospital mortality OR was 0.67 (95% CI, 0.45–
1.00; P=0.049). Covariate balance was clearly achieved using
the inverse probability weights, as depicted in the Figure and
Figures S1 and S2.
Discussion
In the current study, we compared clinical presentation, risk
factors, in-hospital course, and mortality, stratified by smoking
status, in a large group of patients hospitalized with acute HF.
CS subjects were younger and had a lower risk profile
compared with CN subjects. The in-hospital mortality rates
were also significantly lower in CS patients before and more so
after covariate adjustment. After using the PS-derived inverse
probability of exposure weights, the smoking effect weakened
and was no longer statistically significant. Given our results,
we may be looking at reverse causality: healthier patients are
more likely to continue to smoke. The smoking advantage
Table 1. Continued
Characteristics
Smokers
(n=1103; 22%)
Nonsmokers
(n=3902; 78%) P Value
Cause
Noncompliance with medications 209 (19) 755 (19) 0.77
Noncompliance with diet 18 (1.6) 118 (3) 0.01
Acute coronary syndromes 428 (39) 937 (24) 0.001
Uncontrolled hypertension 77 (7) 333 (8.5) 0.10
Uncontrolled arrhythmia 42 (4) 259 (6.6) 0.001
Anemia 24 (2) 130 (3) 0.05
Infection 130 (12) 601 (15) 0.003
Data are given as number (percentage), unless otherwise indicated. Analyses were performed using Student t test, Wilcoxon-Mann-Whitney test, or Pearson’s v2 test, wherever appropriate.
AF indicates atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
HbA1c, glycated hemoglobin; HF, heart failure; HR, heart rate; IQR, interquartile range; LV, left ventricular; LVEF, LV ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide;
PVD, peripheral vascular disease; RR, respiratory rate; TIA, transient ischemic attack.
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demonstrated after covariate adjustment may be because the
latter has been inadequate, as we have demonstrated herein
and which has also been suggested by others.22 However,
there have been studies suggesting attenuated endothelial
dysfunction23 in CS subjects, although this may still reflect
less severity of illness and, thus, reverse causality. Some
researchers suggest that it is the smoking cessation enforced
by hospitalization that improves outcome,10 although this is
unlikely because of the result of this study.
From first mention of the smoker’s paradox in 1995 and in
the 15 years after this, there had been 7 randomized trials and
10 observational studies/registries published presenting the
idea of the smoker’s paradox in ACS3 but only one onHF per se.2
Since then, several studies using covariate adjustment have
shown that CS status is protective. In one study, which defined
CS to also include patients reported to have quit smoking during
the past year, the in-hospital mortality rate was lower in
smokers, but smoking status was not an independent predictor
of mortality.24 This paradoxical result can also be shown in
young patients with acute MI in whom CS was an independent
predictor of 8-month cardiac death (OR, 0.25; 95% CI, 0.07–
0.92; P=0.037) and total death (OR, 0.26; 95% CI, 0.09–0.82;
P=0.021).25 The same has been found for the benefit resulting
from routine early invasive management of unselected patients
with acute non–ST-segment–elevation MI, in whom the treat-
ment effect of an early invasive strategy was more pro-
nounced among CSs and not entirely explained by covariate
adjustment.26 Finally, the only study in HF, to date, has
demonstrated that someone who has smoked cigarettes any
time during the year before hospital arrival (which was how
CS was defined) had a better prognosis than CNs (labeled in
their article as “nonsmokers”).2
PS analyses have also been previously done. One study
that examined 29 199 patients with acute MI found that 42%
were CS subjects, and the hazard ratio (HR) was 0.52 (95% CI,
0.47–0.58; P<0.001), in favor of reduced mortality in the CS
subjects at up to 1 year after acute MI. Covariate adjustment
attenuated the effect, but the HR remained statistically
significant (HR, 0.85; 95% CI, 0.76–0.95; P=0.005). However,
the use of PS matching corroborated the results of reduced
mortality among CSs (6.7% versus 7.6%; P=0.005).27 This
suggests that PS matching may not be as effective as PS-
based weighting. Indeed, in other studies that have used PS-
based weights, the CS factor lost its influence in prognosis
and the authors suggest that the smoking paradox is a finding
that could be explained by other prognostic factors.28 This
may also explain why CS seems to impart a covariate-
adjusted survival benefit in patients with other conditions,
such as traumatic injuries.5
In studies of smoking cessation on subjects with left
ventricular dysfunction after MI using PS-adjusted Cox
proportional hazard models, the benefit of this cessation
has been confirmed.29 In baseline smokers who survived to
6 months without interval events, smoking cessation at 6-
month follow-up was associated with a significantly lower
Table 2. In-Hospital Course of Registry Subjects
Variables
Smokers
(n=1103; 22%)
Nonsmokers
(n=3902; 78%) P Value
In-hospital course
NIV 79 (7.2) 394 (10) 0.003
Intubation/ventilation 97 (8.8) 327 (8.4) 0.66
Inotropes 231 (21) 552 (14) 0.001
IABP insertion 21 (2) 61 (1.6) 0.43
Acute dialysis/
ultrafiltration
16 (1.5) 119 (3) 0.004
VT/VF requiring therapy 74 (6.7) 148 (3.8) 0.001
AF requiring therapy 48 (4.4) 263 (6.7) 0.004
Major bleeding 2 (0.2) 38 (1.0) 0.009
Blood transfusion 28 (2.5) 226 (5.8) 0.001
Stroke 13 (1.2) 55 (1.4) 0.56
Systemic infection
requiring antibiotics
229 (21) 979 (25) 0.003
Cardiac procedures
PCI 112 (10) 187 (5) 0.001
CABG 20 (2) 49 (1.3) 0.16
Discharge medications
Digoxin 306 (28) 901 (23) 0.001
Oral nitrates 405 (37) 1417 (36) 0.81
Hydralazine 42 (4) 311 (8) 0.001
Aspirin 925 (84) 2926 (75) 0.001
Clopidogrel 522 (47) 1276 (33) 0.001
Oral anticoagulants 157 (14) 740 (19) 0.001
Statin 775 (70) 2660 (68) 0.19
Ivabradine 66 (6) 173 (4.4) 0.03
Antiarrhythmic 57 (5) 187 (5) 0.61
b Blockers 798 (72) 2564 (66) 0.001
ACE inhibitors 753 (68) 2129 (55) 0.001
ARBs 160 (15) 642 (17) 0.12
Aldosterone antagonists 526 (48) 1530 (39) 0.001
Diuretics 975 (88) 3489 (89) 0.32
Length of stay,
median (IQR), d
7 (4–10) 6 (4–11) 0.16
In-hospital mortality 53 (4.8) 260 (6.7) 0.02
Data are given as number (percentage), unless otherwise indicated. Analyses were
performed using Student t test, Wilcoxon-Mann-Whitney test, Pearson’s v2 test, or Fisher
exact test, wherever appropriate. ACE indicates angiotensin-converting enzyme; AF,
atrial fibrillation; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass
grafting; IABP, intra-aortic balloon pump; IQR, interquartile range; NIV, noninvasive
ventilation; PCI, percutaneous coronary intervention; VF, ventricular fibrillation; VT,
ventricular tachycardia.
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adjusted risk of all-cause mortality (HR, 0.57; 95% CI, 0.31–
0.91), death or recurrent MI (HR, 0.68; 95% CI, 0.47–0.99),
and death or acute HF hospitalization (HR, 0.65; 95% CI,
0.46–0.92).29 These findings indicate that within a CS cohort,
smoking cessation (beyond hospital admission) is beneficial
after high-risk MI, and this clearly indicates that smoking
cannot be causally related to better prognosis if cessation
itself leads to better prognosis. Other studies have shown that
smoking is associated with lower 30-day mortality (HR, 0.91;
95% CI, 0.87–0.94) but higher long-term mortality (17-year
HR, 1.19; 95% CI, 1.17–1.20) after acute MI, in keeping with
the hypothesis that continuing to smoke on admission is
essentially a marker of a reduced severity of illness in terms
of the underlying diagnosis.30 Overall, crude life expectancy
estimates are also lower for smokers than nonsmokers at all
ages, which translates into sizeable numbers of life-years lost
attributable to smoking.30 Given these and other similar
findings,31 it is unlikely that the covariate-adjusted estimates
reported do imply causality. Finally, a recent study of HF has
shown that if never smokers are the reference category, then
there is a worse prognosis for CS.32 This suggests that
smoking per se is harmful, but quitting because of illness on
its own selects out those who have a worse prognosis. We
could not test this hypothesis using our data as never
smokers were not identified.
This study has a limitation of evaluating smoking history only
at admission. In other words, people were classified as CSs or
CNs. Thus, the burden of smoking was ignored and only
behavior on admission was assessed. Therefore, the results in
this article indicate the prognostic value of the smoking
behavior at one time point (admission) and do not reflect the
morbidity caused by smoking. This classification is in keeping
with other epidemiological studies published previously.33
Another limitation is that with PS methods, there is the issue
of extreme weights. It has been suggested that an analysis be
done on a subsample with PS between 0.1 and 0.9. In the case
of this study, this eliminates 41% of the sample and, thus, is ill
advised. We suggest creating a subsample with PS between
0.01 and 0.99 as this limits the exclusions markedly. However,
with either subsample, covariate balance was achieved, more
so with PS values between 0.1 and 0.9.
We conclude that in studies of HF or of ACS, conditioning
on the PS-derived weight is better and obviates the need for
adjustment. In addition, PS techniques allow one to measure
Figure. All subjects included. Covariate balance after using the inverse probability weights; horizontal
lines denoting standardized differences of 0.1; standardized differences that exceed thresholds are
indicative of meaningful imbalance. Circles indicate standardized differences before propensity score (PS)
adjustment, and squares indicate standardized differences after PS adjustment. acs Indicates precipitating
acute coronary syndrome; admitHF, previous admission for heart failure; admitTO, where admitted in
hospital; AFther, had atrial fibrillation requiring therapy; agecat, age category; aspirin, on aspirin before
admission; AsthCOPD, history of asthma or chronic obstructive pulmonary disease; BMIgrp, body mass
index category; CAD, coronary artery disease; ckddial, history of chronic kidney disease or dialysis; country,
country of hospitalization; DM, diabetes mellitus; hilipid, history of hyperlipidemia; intvent, was intubated
and/or on a ventilator; nyha, New York Heart Association class (heart failure); syncope, history of syncope
in the past 1 year.
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marginal (or population-average) treatment effects as
opposed to covariate adjustment-based approaches that
allow one to estimate conditional (or adjusted) estimates of
treatment effects. However, a recent evaluation of PS versus
covariate adjustment in 4 large cardiovascular observational
studies did not reveal a major difference between covariate
adjustment and PS methods.9 This may be the case when
confounding variables are not many, but if there are a
multitude of confounders, then clearly PS methods are
superior. The novel parts of this study include demonstration
of this paradox in a Middle Eastern population and the
documentation of residual confounding, even after accounting
for known confounders in this understudied population. It is
possible that such unknown confounders could be specific to
this particular population and similarly hypothesized for other
population studies. This paradox may be investigated further
by collecting data on never smokers and using them as the
reference for the analysis, but this needs to be tested in
future studies or with existing data. Finally, we should point
out that we examined potential confounding in this article as
an explanation for the paradoxical results. Others34 have
looked at the potential for paradoxical results caused by
collider stratification bias (a form of selection bias). Obviously,
if we balance/stratify/adjust on a collider, we introduce,
rather than remove, bias, as indicated by Lajous et al34; in
their article, DM was a collider when the obesity-mortality
relationship was being examined and, thus, adjusting for or
stratifying on DM induced bias, with strata based on DM
having opposite associations. In the case of the “current
smoking” behavior at admission and its association with
mortality, all variables we adjust for or balance are con-
founders determined a priori by examining their putative
association with exposure and outcome.
Conclusions
Our study shows that there is no survival advantage for CSs in
patients hospitalized with HF. The current study underlines the
need for future studies to also review the smoker`s paradox
phenomena reported in other chronic conditions with appro-
priate covariate balancing as this may demystify erroneous
conclusions currently present in the medical literature. In
addition, future studies should also focus on discovering the
effect of unknown confounders using novel statistical methods,
such as machine learning and use of electronic health records,
which have a potential to improve our understanding of residual
confounding in studies of chronic diseases.
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Figure S1. Limited to PS between 0.01 and 0.99. 
 
 
Covariate balance after using the inverse probability weights; horizontal lines denoting 
standardized differences of ±0.1, standardized differences that exceed thresholds indicative of 
meaningful imbalance. Circles indicate standardized differences prior to PS adjustment and 
squares indicate standardized differences after PS adjustment. agecat=Age category; 
ckddial=History of CKD or dialysis; hilipid=History of hyperlipidemia; acs=Precipitating acute 
coronary syndrome; aspirin=On aspirin before admission; nyha=NYHA Class (heart failure); 
AFther=Had atrial fibrillation requiring therapy; AsthCOPD=History of asthma or COPD; 
BMIgrp=BMI category; country=Country of hospitalization; intvent=Was intubated and/or on a 
ventilator; syncope=History of syncope in the last one year; admitHF=Previous admission for 
heart failure; admitTO=Where admitted in hospital. 
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Figure S2. Limited to PS between 0.1 and 0.9.  
 
 
Covariate balance after using the inverse probability weights; horizontal lines denoting 
standardized differences of ±0.1, standardized differences that exceed thresholds indicative of 
meaningful imbalance. Circles indicate standardized differences prior to PS adjustment and 
squares indicate standardized differences after PS adjustment. agecat=Age category; 
ckddial=History of CKD or dialysis; hilipid=History of hyperlipidemia; acs=Precipitating acute 
coronary syndrome; aspirin=On aspirin before admission; nyha=NYHA Class (heart failure); 
AFther=Had atrial fibrillation requiring therapy; AsthCOPD=History of asthma or COPD; 
BMIgrp=BMI category; country=Country of hospitalization; intvent=Was intubated and/or on a 
ventilator; syncope=History of syncope in the last one year; admitHF=Previous admission for 
heart failure; admitTO=Where admitted in hospital.  
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